Any more thought about the P2b trial? We all know the P3 is required but the P2b trial remains to be a grey area on this board. Can't help but wonder if it will still be required given the positive results that we continue to see on P2a. And given the disease, I assume Anavex will at some point submit a request for the FDA Fast-Track designation to speed up the review and approval process. Your thoughts? TIA
Of course even then there'd still need to be the double-blind, placebo-controlled P2b/P3 trial.